A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 4
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
- Evidence population
- Human clinical study registration
- Participants
- 332
- Population
- ALL · 50 Years
- Duration
- 2013-02-22 to 2015-11-23
- Intervention
- Ranibizumab
- Comparator
- Not reported
- Outcomes measured
- Average Change in Visual Acuity (Letters) From Month 3 to Month 4 Through Month 12 — Month 3 to month 4 through Month 12; Average Visual Acuity Change (Letters) From Month 3 to Month 4 Through Month 24 — Month 3 to month 4 through Month 24; Average Visual Acuity Change From Baseline to Month 1 Through Month 12 and Month 1 Through Month 24 — Baseline to Month…; Change From Baseline in Visual Acuity (Letters) of the Study Eye Over Time — Baseline to 24 months; Number of Patients With a BCVA Improvement of ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 24 — Baseline to Mon…; Number of Patients With a BCVA Loss of 15 Letters in the Study Eye Over Time — Baseline to Month 24; Number of Patients With a Best Corrected Visual Acuity (BCVA) of More of 73 Letters or More — Month 12 and 24; Change From Baseline in Central Sub-Field Thickness (CSFT) of the Study Eye Over Time to Month 12 and Month 24 — Baseli…; Duration of Ranibizumab Treatment Free Interval in the Study Eye up to Month 24 — up to month 24; Duration of Ranibizumab Treatment Free Interval in the Study Eye Prior to Month 12 — prior to month 12; Duration of Active Treatment Phase Prior to Month 12 — Prior to month 12; Duration of Active Treatment Phase up to Month 24 — up to month 24
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Summary supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.